HSK41959

DRUG2 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

Advanced Solid TumorsNon-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma (mPDAC)

Phase 1

Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion

RecruitingNCT06968572

Haisco Pharmaceutical Group Co., Ltd.Advanced Solid Tumors

Start: 2025-04-11End: 2028-05-08Target: 245Updated: 2025-05-13

HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion

Not yet recruitingNCT07699757

Haisco Pharmaceutical Group Co., Ltd.Advanced Solid Tumors, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)

Start: 2026-07-01End: 2029-11-01Target: 258Updated: 2026-07-14

Related Papers

First-in-human phase I study of HSK41959, an MTA-cooperative PRMT5 inhibitor, in patients with <i>MTAP</i> -deleted advanced solid tumors.

Journal of Clinical Oncology2026-05-28